JP7713129B1 - 組成物 - Google Patents

組成物

Info

Publication number
JP7713129B1
JP7713129B1 JP2025520933A JP2025520933A JP7713129B1 JP 7713129 B1 JP7713129 B1 JP 7713129B1 JP 2025520933 A JP2025520933 A JP 2025520933A JP 2025520933 A JP2025520933 A JP 2025520933A JP 7713129 B1 JP7713129 B1 JP 7713129B1
Authority
JP
Japan
Prior art keywords
gly
composition
peptide
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025520933A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025142861A5 (https=
JPWO2025142861A1 (https=
Inventor
孝太郎 坂元
英次郎 都
由希夫 吾郷
晋作 中川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hiroshima University NUC
Japan Advanced Institute of Science and Technology
Ichimaru Pharcos Co Ltd
University of Osaka NUC
Original Assignee
Hiroshima University NUC
Japan Advanced Institute of Science and Technology
Osaka University NUC
Ichimaru Pharcos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroshima University NUC, Japan Advanced Institute of Science and Technology, Osaka University NUC, Ichimaru Pharcos Co Ltd filed Critical Hiroshima University NUC
Publication of JPWO2025142861A1 publication Critical patent/JPWO2025142861A1/ja
Application granted granted Critical
Publication of JP7713129B1 publication Critical patent/JP7713129B1/ja
Publication of JPWO2025142861A5 publication Critical patent/JPWO2025142861A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2025520933A 2023-12-28 2024-12-23 組成物 Active JP7713129B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023223187 2023-12-28
JP2023223187 2023-12-28
PCT/JP2024/045520 WO2025142861A1 (ja) 2023-12-28 2024-12-23 組成物

Publications (3)

Publication Number Publication Date
JPWO2025142861A1 JPWO2025142861A1 (https=) 2025-07-03
JP7713129B1 true JP7713129B1 (ja) 2025-07-24
JPWO2025142861A5 JPWO2025142861A5 (https=) 2025-11-26

Family

ID=96217889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025520933A Active JP7713129B1 (ja) 2023-12-28 2024-12-23 組成物

Country Status (2)

Country Link
JP (1) JP7713129B1 (https=)
WO (1) WO2025142861A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022522940A (ja) * 2019-01-07 2022-04-21 ユーシーエル ビジネス リミテッド 複数のリガンドで機能化されたポリマーソーム

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119630790A (zh) * 2022-08-05 2025-03-14 一丸自然美健有限公司 新型lrp1结合肽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022522940A (ja) * 2019-01-07 2022-04-21 ユーシーエル ビジネス リミテッド 複数のリガンドで機能化されたポリマーソーム

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
SAKAMOTO K. et al.，Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activi，Frontiers in Pharmacology，2021年，Vol.12, Article 751587，<doi: 10.3389/fphar.2021.751587>
SAKAMOTO K. ET AL.: "Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activi", FRONTIERS IN PHARMACOLOGY, vol. Vol.12, Article 751587, JPN6025010325, 2021, ISSN: 0005611361 *
SAKAMOTO K.，Generation of KS-487 as a novel LRP1-binding cyclic peptide with higher affinity, higher stability a，Biochemistry and Biophysics Reports，2022年，Vol.32, 101367，<https://doi.org/10.1016/j.bbrep.2022.101367>
SAKAMOTO K.: "Generation of KS-487 as a novel LRP1-binding cyclic peptide with higher affinity, higher stability a", BIOCHEMISTRY AND BIOPHYSICS REPORTS, vol. Vol.32, 101367, JPN6025010324, 2022, ISSN: 0005611363 *
SHAO K. et al.，Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brai，Journal of Controlled Release，2010年，Vol.147, pp.118-126，<doi:10.1016/j.jconrel.2010.06.018>
SHAO K. ET AL.: "Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brai", JOURNAL OF CONTROLLED RELEASE, vol. Vol.147, pp.118-126, JPN6025010323, 2010, ISSN: 0005611362 *

Also Published As

Publication number Publication date
WO2025142861A1 (ja) 2025-07-03
JPWO2025142861A1 (https=) 2025-07-03

Similar Documents

Publication Publication Date Title
TWI482626B (zh) 胃腸道病症的治療
JP2026027576A (ja) Ｒａｓ阻害ペプチドを含む組成物
US20050048063A1 (en) Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US20090047335A1 (en) Anti-angiogenic peptides and methods of use thereof
US20160375145A1 (en) Etoposide and doxorubicin conjugates for drug delivery
EP2649095B1 (en) Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
US11046739B2 (en) BH4 stabilized peptides and uses thereof
JP2001519769A (ja) Ｎ―（アリール／ヘテロアリール）アミノ酸誘導体、その医薬組成物および該化合物を用いたβ―アミロイドペプチドの放出および／またはその合成を阻害する方法
CN110981941A (zh) 生物模拟肽和生物可降解的递送平台
EP4011905A2 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
JP2025138792A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP2022115974A (ja) 化学療法誘発性末梢性ニューロパシーおよび難聴を処置または予防するためのｂｃｌ－ｗポリペプチドおよび模倣物
JP2025120320A (ja) Ｖｉｐｒ２アンタゴニストペプチド
JP6994054B2 (ja) 白血球動員をブロックするペプチドおよび使用方法
JP7713129B1 (ja) 組成物
KR102415717B1 (ko) 혈액뇌장벽 투과능을 가지는 신규한 펩타이드 및 이의 용도
JP2017519740A (ja) ドラプロイン‐ドライソロイインペプチド誘導体
JP7417010B1 (ja) 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド
US11891456B2 (en) Amyloid inhibitory peptides
CN107406513A (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
CN113412116A (zh) 用于心脏保护的经修饰的轴突生长诱向因子-1肽和组合物
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
WO2025006536A2 (en) Factor xii binding peptides and methods of use
US20210228677A1 (en) Pharmaceutical composition and a method for its manufacture
US20200347136A1 (en) Constrained cyclic peptides as inhibitors of the cd2:cd58 protein-protein interaction for treatment of diseases and autoimmune disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250410

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

R150 Certificate of patent or registration of utility model

Ref document number: 7713129

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350